Timing of Palliative Care Referral Before and After Evidence from Trials Supporting Early Palliative Care.
Cancer
Early medical intervention
Health care quality, access and evaluation
Health services accessibility
Health services research
Outcome assessment, healthcare
Outpatient clinics, hospital
Palliative care
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
07
05
2020
accepted:
20
11
2020
pubmed:
8
12
2020
medline:
22
6
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Evidence from randomized controlled trials has demonstrated benefits in quality of life outcomes from early palliative care concurrent with standard oncology care in patients with advanced cancer. We hypothesized that there would be earlier referral to outpatient palliative care at a comprehensive cancer center following this evidence. Administrative databases were reviewed for two cohorts of patients: the pre-evidence cohort was seen in outpatient palliative care between June and November 2006, and the post-evidence cohort was seen between June and November 2015. Timing of referral was categorized, according to time from referral to death, as early (>12 months), intermediate (>6 months to 12 months), and late (≤6 months from referral to death). Univariable and multivariable ordinal logistic regression analyses were used to determine demographic and medical factors associated with timing of referral. Late referrals decreased from 68.8% pre-evidence to 44.8% post-evidence; early referrals increased from 13.4% to 31.1% (p < .0001). The median time from palliative care referral to death increased from 3.5 to 7.0 months (p < .0001); time from diagnosis to referral was also reduced (p < .05). On multivariable regression analysis, earlier referral to palliative care was associated with post-evidence group (p < .0001), adjusting for shorter time since diagnosis (p < .0001), referral for pain and symptom management (p = .002), and patient sex (p = .04). Late referrals were reduced to <50% in the breast, gynecological, genitourinary, lung, and gastrointestinal tumor sites. Following robust evidence from trials supporting early palliative care for patients with advanced cancer, patients were referred substantially earlier to outpatient palliative care. Following published evidence demonstrating the benefit of early referral to palliative care for patients with advanced cancer, there was a substantial increase in early referrals to outpatient palliative care at a comprehensive cancer center. The increase in early referrals occurred mainly in tumor sites that have been included in trials of early palliative care. These results indicate that oncologists' referral practices can change if positive consequences of earlier referral are demonstrated. Future research should focus on demonstrating benefits of early palliative care for tumor sites that have tended to be omitted from early palliative care trials.
Sections du résumé
BACKGROUND
Evidence from randomized controlled trials has demonstrated benefits in quality of life outcomes from early palliative care concurrent with standard oncology care in patients with advanced cancer. We hypothesized that there would be earlier referral to outpatient palliative care at a comprehensive cancer center following this evidence.
MATERIALS AND METHODS
Administrative databases were reviewed for two cohorts of patients: the pre-evidence cohort was seen in outpatient palliative care between June and November 2006, and the post-evidence cohort was seen between June and November 2015. Timing of referral was categorized, according to time from referral to death, as early (>12 months), intermediate (>6 months to 12 months), and late (≤6 months from referral to death). Univariable and multivariable ordinal logistic regression analyses were used to determine demographic and medical factors associated with timing of referral.
RESULTS
Late referrals decreased from 68.8% pre-evidence to 44.8% post-evidence; early referrals increased from 13.4% to 31.1% (p < .0001). The median time from palliative care referral to death increased from 3.5 to 7.0 months (p < .0001); time from diagnosis to referral was also reduced (p < .05). On multivariable regression analysis, earlier referral to palliative care was associated with post-evidence group (p < .0001), adjusting for shorter time since diagnosis (p < .0001), referral for pain and symptom management (p = .002), and patient sex (p = .04). Late referrals were reduced to <50% in the breast, gynecological, genitourinary, lung, and gastrointestinal tumor sites.
CONCLUSIONS
Following robust evidence from trials supporting early palliative care for patients with advanced cancer, patients were referred substantially earlier to outpatient palliative care.
IMPLICATIONS FOR PRACTICE
Following published evidence demonstrating the benefit of early referral to palliative care for patients with advanced cancer, there was a substantial increase in early referrals to outpatient palliative care at a comprehensive cancer center. The increase in early referrals occurred mainly in tumor sites that have been included in trials of early palliative care. These results indicate that oncologists' referral practices can change if positive consequences of earlier referral are demonstrated. Future research should focus on demonstrating benefits of early palliative care for tumor sites that have tended to be omitted from early palliative care trials.
Identifiants
pubmed: 33284483
doi: 10.1002/onco.13625
pmc: PMC8018311
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
332-340Informations de copyright
© 2020 AlphaMed Press.
Références
BMC Palliat Care. 2014 Dec 16;13(1):59
pubmed: 25550683
BMJ Open. 2020 Jan 7;10(1):e034378
pubmed: 31915175
Psychooncology. 2012 Sep;21(9):977-85
pubmed: 21671304
Ann Oncol. 2012 Feb;23(2):382-7
pubmed: 21804051
Support Care Cancer. 2020 Feb;28(2):877-885
pubmed: 31165335
Support Care Cancer. 2009 Sep;17(9):1223-30
pubmed: 19184126
CMAJ. 2016 Jul 12;188(10):E217-E227
pubmed: 27091801
Support Care Cancer. 2018 Jan;26(1):175-180
pubmed: 28726065
Oncologist. 2017 Dec;22(12):1528-1534
pubmed: 28894017
Gynecol Oncol. 2018 Mar;148(3):521-526
pubmed: 29395315
J Pain Symptom Manage. 2016 Feb;51(2):262-9
pubmed: 26482223
J Pain Symptom Manage. 2003 Feb;25(2):150-68
pubmed: 12590031
J Clin Oncol. 2015 May 1;33(13):1438-45
pubmed: 25800768
Cancer. 2015 Sep 1;121(17):3027-35
pubmed: 26059846
CA Cancer J Clin. 2018 Sep;68(5):356-376
pubmed: 30277572
JAMA. 2016 Nov 22;316(20):2104-2114
pubmed: 27893131
Eur J Cancer. 2016 Sep;65:61-8
pubmed: 27472648
Lancet Oncol. 2016 Dec;17(12):e552-e559
pubmed: 27924753
Lancet Oncol. 2018 Nov;19(11):e588-e653
pubmed: 30344075
Lancet Oncol. 2018 Mar;19(3):394-404
pubmed: 29402701
Support Care Cancer. 2016 Sep;24(9):3873-81
pubmed: 27086311
BMJ Support Palliat Care. 2019 Aug 12;:
pubmed: 31406013
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Lancet. 2014 May 17;383(9930):1721-30
pubmed: 24559581
J Oncol Pract. 2017 Sep;13(9):578-579
pubmed: 28898606
J Clin Oncol. 2012 Dec 10;30(35):4380-6
pubmed: 23109708
J Clin Oncol. 2011 Mar 20;29(9):1151-8
pubmed: 21300920
JAMA Intern Med. 2013 Feb 25;173(4):283-90
pubmed: 23358690
Cancer. 2009 May 1;115(9):2013-21
pubmed: 19235253
Indian J Palliat Care. 2019 Jan-Mar;25(1):153-155
pubmed: 30820119
Cochrane Database Syst Rev. 2017 Jun 12;6:CD011129
pubmed: 28603881
JAMA. 2008 Apr 9;299(14):1698-709
pubmed: 18398082
Palliat Med. 2017 Oct;31(9):814-824
pubmed: 28494643
Breast Cancer Res Treat. 2018 Feb;167(3):703-708
pubmed: 29086230
Support Care Cancer. 2018 Nov;26(11):3951-3958
pubmed: 29850945
J Palliat Med. 2018 Sep;21(9):1322-1328
pubmed: 29630413
Palliat Med. 2017 Jan;31(1):72-81
pubmed: 27495814
J Clin Oncol. 2012 Mar 10;30(8):880-7
pubmed: 22312101
Ann Oncol. 2018 Jan 1;29(1):36-43
pubmed: 29253069
J Oncol Pract. 2017 Feb;13(2):119-121
pubmed: 28972832
BMJ. 2017 Jul 4;357:j2925
pubmed: 28676557
PLoS One. 2019 Jan 17;14(1):e0210056
pubmed: 30653508
JAMA. 2009 Aug 19;302(7):741-9
pubmed: 19690306